[Functional urology: synopsis of the 101st Congress of the French Association of Urology]

Functional urology knows more and more a marked development. Regarding benign prostatic hyperplasia, combined treatments are used often and new molecules such as inhibitor of phosphodiesterase of type 5 are appearing. The gold standard treatment of urinary incontinence with sphincteric deficiency remains the artificial urinary sphincter, in men and in women, where the rate of success is nearly of 95 %. The use of botulinic toxin in neurogenic bladder and especially in overactive bladder is growing remarkably, notably in patients of whom quality of life is improve against a very low toxicity. However, the effect of the molecules becomes blurred within a few months. The CT diagnosis of urinary lithiasis is about to provide nowadays the main component of each calculi. Peyronie's disease remains scarce in which verapamil's injections are strongly suggested to amend pain but not the curve during erection.